Anandamide (AEA) Cannabinoid Research

Anandamide (AEA) Research Dashboard

288

Primary Studies

169

Related Studies

457

Total Studies

Clinical Studies

2

Clinical Meta-analyses

5

Double-blind human trials

16

Clinical human trials

Pre-Clinical Studies

90

Meta-analyses/Reviews

96

Animal studies

63

Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 457 studies associated with Anandamide (AEA).

Here is a small sampling of Anandamide (AEA) studies by title:


Components of the Anandamide (AEA) Research Dashboard

  • Top medical conditions associated with Anandamide (AEA)
  • Proven effects in clinical trials for Anandamide (AEA)
  • Receptors associated with Anandamide (AEA)
  • Individual study details for Anandamide (AEA)

Ready to become a subscriber? Go to our PRICING page.

Select New Cannabinoid

Filter Cannabinoid

Members can filter by the following criteria:

  • Study Type
  • Organ Systems
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - Anandamide (AEA)

Description of Anandamide (AEA)

Anandamide was the first endogenous (naturally occurring inside the human body) cannabinoid to be discovered in 1995 by Raphael Mechoulam. Mechoulam and his team named the compound combining the Sanskrit word for bliss, "ananda," and the word "amide" describing an organic chemical compound to arrive at the name anandamide. The naturally occurring enzyme fatty acid amide hydrolase (FAAH) breaks down AEA.

Other Names:

Anandamide (N-arachidonyl ethanolamide)
Anandamide, Arachidonylethanolamide, Arachidonoyl ethanolamide, N-Arachidonoylethanolamine

IUPAC Name: (5Z,8Z,11Z,14Z)-N-(2-hydroxyethyl)icosa-5,8,11,14-tetraenamide

Molecular Formula: C22H37NO2

Source–PubChem

Anandamide (AEA) Properties and Effects

• CB1 and CB2 receptor activation by AEA play a therapeutic role in mitigating pain, improving mood and cognition, and reducing inflammation and oxidative stress, for instance.

• TRPV1 activation by AEA have relevance to immune and cardiovascular functions (vasodilation), inflammation, and pain.

• AEA-base modulation of 5-HT receptors (serotonin) improve mood, reducing stress, fear, anxiety, depression, and pain for instance with potential relevance to the treatment of diverse psychiatric disorders characterized by impairments in social behavior, such as autism or schizophrenia.

• AEA induces anti-inflammatory via PPAR-Gamma.

• In the presence of the corticosteroids (steroidal hormones involved in a number of functions such as stress responses), the body increases its production of AEA, which may account for the way in which the endocannabinoid boosts the antidepressant effects of exercise.

• AEA enhances the experience of pleasure derived from food.

• AEA is capable of destroying numerous types of cancers in the laboratory.

• Oxytocin, a naturally occurring hormone—associated with trust, intimacy, and close and meaningful relationships—increases the production of AEA.

• CBD inhibits the enzyme that breaks down AEA (i.e., FAAH) and as such may increase its presence (or bioavailability of AEA) and with it all the effects it engenders.

• Chronic stress reduces AEA levels whereas relaxation or meditation practices may increase AEA levels naturally

• Electro acupuncture has been shown to increase levels of AEA.

• Osteopathic manipulations have been shown to increase levels of AEA.

Anandamide (AEA) Receptor Binding

Endocannabinoid System
• Agonist at CB1 (Ki range 61-543nM see Howlett et al., 2002) (mean Ki ~241)
• Agonist at CB2 (Ki range 371-1940nM see Howlett et al., 2002) (mean Ki ~785)

Endocannabinoidome (eCBome)
TRPV1
PPAR-α
PPAR-y
5-HT/serotonin allosteric modulation (indirect)

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.